Literature DB >> 6237265

Evidence for an antagonistic action of tabernanthine on hypoxia-induced changes in brain serotonin levels.

E Mocaër-Cretet, M Prioux-Guyonneau, F Redjimi, Y Cohen, C Jacquot.   

Abstract

The effects of tabernanthine on serotonin (5-HT) levels were determined in several brain areas of rats exposed to various simulated altitudes (1800, 5200, 7000 m). The 5-HT synthesis inhibitor, para-chlorophenylalanine (PCPA), was used to dissociate the effects occurring at synthesis and release levels. Tabernanthine antagonized the decrease in hypothalamic 5-HT levels induced by a 7000 m hypoxia and also suppressed the decrease in PCPA-induced depletion observed at 5200 and 7000 m in the hypothalamus, the striatum and the rest of the brain. It was assumed that tabernanthine stimulates different steps of 5-HT metabolism. These effects, revealed by hypoxia, are related to other peripheral and central properties of this drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6237265     DOI: 10.1007/bf00501431

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  22 in total

1.  [SOME PHARMACOLOGICAL PROPERTIES OF 12 NATURAL AND 11 PARTIALLY SYNTHETICALLY DERIVED INDOLE ALKALOIDS FROM TROPICAL APOCYANACEAE OF THE SUB-TRIBE TABERNAEMONTANINAE].

Authors:  G ZETLER
Journal:  Arzneimittelforschung       Date:  1964-12

2.  Changes in biogenic amine synthesis and turnover induced by hypoxia and/or foot shock stress. II. The central nervous system.

Authors:  R M Brown; S R Snider; A Carlsson
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

3.  Comparative effects of p-chloroamphetamine and p-chloro-N-methylamphetamine on rat brain norepinephrine, serotonin and 5-hydroxyindole-3-acetic acid.

Authors:  F P Miller; R H Cox; W R Snodgrass; R P Maickel
Journal:  Biochem Pharmacol       Date:  1970-02       Impact factor: 5.858

4.  gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas.

Authors:  B Scatton; B Zivkovic; J Dedek; K G Lloyd; J Constantinidis; R Tissot; G Bartholini
Journal:  J Pharmacol Exp Ther       Date:  1982-03       Impact factor: 4.030

5.  The effect of hypoxia on brain neurotransmitter systems.

Authors:  J N Davis; L T Giron; E Stanton; W Maury
Journal:  Adv Neurol       Date:  1979

6.  The effect of various stimulated altitudes on the turnover of norepinephrine and dopamine in the central nervous system of rats.

Authors:  M Prioux-Guyonneau; E Cretet; C Jacquot; J R Rapin; Y Cohen
Journal:  Pflugers Arch       Date:  1979-06-12       Impact factor: 3.657

7.  A comparison of an improved o-phthalaldehyde fluorometric method and high pressure liquid chromatography in the determination of brain 5-hydroxyindoles of rats treated with L-tryptophan and p-chlorophenyl-alanine.

Authors:  G Curzon; B D Kantamaneni; M D Tricklebank
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

8.  [Effects of tabernanthine on various cardiovascular parameters in the rat and dog (author's transl)].

Authors:  N Hajo; C Dupont; J Wepierre
Journal:  J Pharmacol       Date:  1981 Nov-Dec

9.  Effect of tabernanthine on the turnover time of brain catecholamines in normal and hypobaric hypoxic rats.

Authors:  E Cretet; M Prioux-Guyonneau; C Jacquot; H Sentenac; J Wepierre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

10.  Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids.

Authors:  G Zetler; G Singbartl; L Schlosser
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

View more
  1 in total

1.  Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies.

Authors:  P A Broderick; F T Phelan; F Eng; R T Wechsler
Journal:  Pharmacol Biochem Behav       Date:  1994-11       Impact factor: 3.533

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.